CDT Equity Inc. is the renamed successor to Murphy Canyon Acquisition Corp., a special purpose acquisition vehicle that closed its business combination with Conduit Pharmaceuticals Limited in late 2023 and has reinvented itself twice since then. The company now describes itself as a drug re-purposing platform built around an equity-method stake in Sarborg Limited, an artificial-intelligence business that maps disease signatures for re-positioning clinical-stage compounds. The thesis on the name rests on whether the Sarborg relationship becomes a license-deal pipeline generator or remains a related-party drain on the balance sheet, and on whether the Cambridge co-crystallization technology can outlast the patent entitlement challenge brought by St George Street Capital at the UK Intellectual Property Office. The combination of a going concern qualification, five reverse stock splits, and a recent share-issuance sequence that pushed the diluted count from a six-figure base into the seven-figure range makes the equity structurally binary.
The most recent reported quarter shows a six-month operating loss of $6.7 million against a multi-year accumulated deficit, with cash on hand of less than $1 million at quarter-end. An at-the-market facility provides roughly $73.6 million of theoretical headroom net of an outstanding $8 million cash obligation to the Sarborg sellers. The disclosed working-capital requirement for the next twelve months is just over $20 million under stated assumptions. The post-period event in late August reshaped the equity story: stockholders approved pre-funded warrants for roughly 12.1 million shares to Sarborg investors, which were cashless-exercised to produce an implied market capitalization of approximately $23 million at the August closing print. The sequence cured the Nasdaq minimum-bid-price deficiency that had hung over the listing.
The forward variables are concentrated in three near-term triggers. The first is the closure and accounting of the second Sarborg purchase, which lifts CDT's economic interest toward 25% on a fully diluted basis. The second is the outcome of the co-crystal patent entitlement proceeding, where St George Street Capital contests ownership and the company has accrued no loss contingency. The third is the pace of at-the-market share issuance against the remaining Sales Agreement capacity, which functions as both a financing tool and a slow-motion dilution mechanism. The bull case rests on Sarborg generating license-deal flow that lifts the equity-method investment above its current carrying value; the bear case rests on the company running out of authorized shares before any license revenue materializes.